We are a clinical-stage biopharmaceutical company committed to developing oral drugs for chronic respiratory diseases, focusing on the high unmet need of COPD patients.

2024年4月10日 · EP395 is the most advanced of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides™’, which reduce inflammation while also limiting the antimicrobial …

We are dedicated to improving the lives of those affected by chronic respiratory diseases with our new oral treatment, glasmacinal.

The contribution of the epi- and endocardial as well as the myocardial electrical activity to the body surface potentials was investigated in this study. A volume conductor model including a …

In the current study, we used simultaneous endo-epi phase mapping to characterize endo-epi activation patterns on long segments of human persistent AF. Methods: Simultaneous …

Developer of drugs and proprietary compounds intended to offer new treatments for chronic airway diseases.

Endocardial-epicardial (Endo-epi) catheter ablation (CA) has been shown to reduce the rate of ventricular arrhythmia (VA) ablation in patients with structural heart disease (SHD). However, …

2024年3月13日 · Simultaneous epicardial and endocardial (epi-endo) mapping was shown to facilitate a 3D delineation of VT circuits, which is however difficult via invasive mapping.

EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic …

2024年3月13日 · Simultaneous epicardial and endocardial (epi-endo) mapping was shown to facilitate a 3D delineation of VT circuits, which is however difficult via invasive mapping.